A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52 Antibody [alemtuzumab]) Therapy in Newly Diagnosed Subjects With Type 1 Diabetes Mellitus

Trial Profile

A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52 Antibody [alemtuzumab]) Therapy in Newly Diagnosed Subjects With Type 1 Diabetes Mellitus

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 12 Oct 2015

At a glance

  • Drugs Alemtuzumab (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Jan 2008 Trial withdrawn prior to patient recruitment as reported by ClinicalTrials.gov.
    • 04 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top